slides · global inventory
Analyze Data
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 58,039
Current window 33,031-33,060
Pages 1,935
Rows per page 30
Slide function
33,031-33,060 of 58,039
28
The data shows a clear trend where the combination of iNKT activator + Fc enhanced CTLA-4 + PD-1 (Group F) results in the lowest number of metastases.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
30
The table displays patient characteristics (age, sex) and disposition (early discontinuation, death, progression) for three distinct dosing groups and the total population.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
31
The chart displays patient outcomes over time, with dots indicating progression and bars indicating stable disease.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
32
Includes a table of adverse events, box plots for cytokines (IL-1b, IL-6, CRP), and a longitudinal line chart for IFNy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
35
The slide presents clinical trial safety data including a table of adverse events and dot plots for inflammatory markers.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
55
The slide illustrates the CARDIS platform workflow and the resulting distribution of binders vs non-binders.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
67
Clinical trial data summary table.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
68
The slide uses a Kaplan-Meier survival curve, a frequency table for adverse events, and box-and-whisker plots for cytokine levels.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
69
Data presented by Saint John's Cancer Institute for MiNK Therapeutics.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
73
The slide uses a dual-panel layout to contrast pro-inflammatory responses in solid tumors with anti-inflammatory responses in ARDS.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
83
The slide uses scRNA-seq data to correlate cell states (Steady State, 4h, 72h post-activation) with specific metabolic gene modules.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
84
Includes a cartoon illustration of a person cooking, likely representing a researcher or experimental process.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
86
Flow cytometry plots show higher purity/persistence for Gen 2. Bar charts show statistically significant differences (*) in cell count, tumor volume, and metabolic markers.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
88
The slide uses UMAP dimensionality reduction to visualize gene expression density across cell populations.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
90
Data from Lynch et al. Nature Immunology 2015 and Lynch et al. Immunity 2012.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
03
Includes footnotes referencing specific financial metrics and reporting periods.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
04
Includes four charts: two bar charts, one stacked bar chart, and one donut chart.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
05
The slide includes a stacked bar chart showing funding composition from 2017 to 3Q22, alongside descriptive boxes for each funding category.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
06
Includes footnotes referencing specific financial metrics and regulatory ratios.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
07
Includes stacked bar chart for historical growth, pie chart for loan composition, and table for credit quality metrics.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
08
The slide provides a snapshot of creditworthiness across different debt instruments and entities.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
07
Economic ownership calculated off of fully diluted share count of 185.4M inclusive of affiliated shares. Assumes Total Potential Diluted Aggregate Voting Power of 166.9MM votes.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit
09
The table uses a color-coded legend for negative outcomes (red X for no interest, double red X for re-confirmed no interest, yellow double X for not engaged).Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit
10
Includes a timeline of events leading up to a final bid of $24.90.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit
11
Includes footnotes regarding data sources and dates.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit
20
Includes a highlighted section for management-approved extrapolations (CY26E-CY32E).Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit
24
Includes annotations regarding changes in price target ranges and revenue estimates post-Q2'22 earnings.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Impact & Next Steps1 hit
27
Includes sensitivity adjustments to the cost of equity.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Impact & Next Steps1 hit
11
The slide uses a pie chart to show portfolio concentration and a bulleted list for qualitative highlights and specific performance metrics.New York Community Bancorp | Results Presentation Deck | 26 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Business Model1 hit
12
The slide presents a historical bar chart of the loan portfolio alongside a table of originations and net charge-offs, plus a summary of portfolio statistics.New York Community Bancorp | Results Presentation Deck | 26 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Business Model1 hit